hiv1 integrase inhibitor

Hiv-1 integrase inhibitor is an effective anti-HIV drug.

HIV-1 integrase inhibitor 8 is an inhibitor of HIV-1 integrase, a critical enzyme necessary for the integration step in HIV replication [1].

HIV-1 integrase inhibitor 7 is a potent inhibitor of HIV-1 integrase (IC50: 33.3 nM).

HIV-1 integrase inhibitor 3 is an HIV-1 integrase strand transfer (INST) inhibitor with an IC50 of 2.7 nM.

HIV-1 integrase inhibitor 4 is an HIV-1 integrase strand transfer (INST) inhibitor with an IC50 of 3.7 nM.

HIV-1 integrase inhibitor 2 is used for the treatment of human immunodeficiency virus (HIV) infection.

HIV-1integrase inhibitor 12 (Compound 17) is an inhibitor of HIV-1 integrase with an IC50 of 1.4 nM. It effectively inhibits both HIV-1WT and HIV-1T125A with IC50 values of 7.4 nM and 120 nM, respectively. This compound exhibits metabolic stability and Caco-2 permeability in rats, with favorable pharmacokinetic properties, including good bioavailability (64%) and low clearance rate (0.16 L/hr/kg).

HIV-1 integrase inhibitor 13 (Compound 15) is an inhibitor of HIV-1 integrase, with an IC50 value of 1.8 nM. It can inhibit HIV-1WT and HIV-1T125A, with IC50 values of 21 and 580 nM, respectively.

HIV-1 integrase inhibitor 9 (compound 8a) is a potent inhibitor of HIV-1 RNase H (IC50: 12.3 μM) with antiviral effects.

HIV-1 Integrase Inhibitor 10, an orally active allosteric integrase inhibitor (ALLINI), effectively inhibits the NLRepRluc virus's viral outgrowth in MT-2 cells, exhibiting EC50 values of 3-5 nM. This compound is utilized in the research of Human Immunodeficiency Virus-1 (HIV-1).

HIV-1 integrase inhibitor 11 (compound 5) effectively inhibits HIV-1 integrase (HIV-1integrase), with an IC50 of 125 μM.

HIV-1 inhibitor-6 (3-Pyridinecarboxamide, 1,4-dihydro-1-methyl-N-(5-nitro-1,2-benzisothiazol-3-yl)-4-oxo-) is a potent HIV-1 pre-mRNA selective splicing inhibitor that blocks HIV replication.